1. Home
  2. SKYE vs UNB Comparison

SKYE vs UNB Comparison

Compare SKYE & UNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • UNB
  • Stock Information
  • Founded
  • SKYE 2012
  • UNB 1891
  • Country
  • SKYE United States
  • UNB United States
  • Employees
  • SKYE N/A
  • UNB N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • UNB Major Banks
  • Sector
  • SKYE Health Care
  • UNB Finance
  • Exchange
  • SKYE Nasdaq
  • UNB Nasdaq
  • Market Cap
  • SKYE 108.5M
  • UNB 117.7M
  • IPO Year
  • SKYE N/A
  • UNB 1998
  • Fundamental
  • Price
  • SKYE $4.25
  • UNB $25.99
  • Analyst Decision
  • SKYE Buy
  • UNB
  • Analyst Count
  • SKYE 7
  • UNB 0
  • Target Price
  • SKYE $15.50
  • UNB N/A
  • AVG Volume (30 Days)
  • SKYE 294.2K
  • UNB 5.8K
  • Earning Date
  • SKYE 11-06-2025
  • UNB 10-15-2025
  • Dividend Yield
  • SKYE N/A
  • UNB 5.54%
  • EPS Growth
  • SKYE N/A
  • UNB N/A
  • EPS
  • SKYE N/A
  • UNB 2.01
  • Revenue
  • SKYE N/A
  • UNB $48,950,000.00
  • Revenue This Year
  • SKYE N/A
  • UNB N/A
  • Revenue Next Year
  • SKYE N/A
  • UNB N/A
  • P/E Ratio
  • SKYE N/A
  • UNB $12.93
  • Revenue Growth
  • SKYE N/A
  • UNB 2.99
  • 52 Week Low
  • SKYE $1.14
  • UNB $24.51
  • 52 Week High
  • SKYE $6.51
  • UNB $37.70
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 66.34
  • UNB 45.53
  • Support Level
  • SKYE $3.96
  • UNB $25.72
  • Resistance Level
  • SKYE $4.35
  • UNB $26.07
  • Average True Range (ATR)
  • SKYE 0.28
  • UNB 0.47
  • MACD
  • SKYE 0.09
  • UNB 0.01
  • Stochastic Oscillator
  • SKYE 91.15
  • UNB 21.68

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About UNB Union Bankshares Inc.

Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The company provides retail banking services to individuals and commercial banking services to small and medium-sized corporations, partnerships, and sole proprietorships, as well as nonprofit organizations, local municipalities, and school districts within its market area. In addition, it also offers fiduciary and asset management services through its Asset Management Group.

Share on Social Networks: